Assessment of cancer procoagulant activity in patients with multiple myeloma

Krzysztof Chojnowski, Jacek Treliński, Malgorzata Kamocka, Wojciech P. Mielicki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pathomechanism of coagulation disorders in multiple myeloma (MM) patients is a complex one but most frequently connected with the presence of monoclonal protein. Until today the role of cancer procoagulant (CP) has not been studied in MM. In the paper CP activity in 26 patients with MM was tested. In 31% of patients elevated levels of CP activity above baseline was observed. Mean CP activity was higher in MM group than in control but without statistical significance. No major differences between mean CP activity in II and III stage of the disease MM type, and no correlation between CP activity and the concentration of monoclonal protein was seen. In none of the patients with CP activity above normal any thrombotic complications were observed.

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalActa Haematologica Polonica
Volume36
Issue number1
StatePublished - 2005
Externally publishedYes

Fingerprint

cancer procoagulant
Multiple Myeloma
Proteins

Keywords

  • Cancer procoagulant
  • Myeloma multiplex
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Assessment of cancer procoagulant activity in patients with multiple myeloma. / Chojnowski, Krzysztof; Treliński, Jacek; Kamocka, Malgorzata; Mielicki, Wojciech P.

In: Acta Haematologica Polonica, Vol. 36, No. 1, 2005, p. 73-79.

Research output: Contribution to journalArticle

Chojnowski, K, Treliński, J, Kamocka, M & Mielicki, WP 2005, 'Assessment of cancer procoagulant activity in patients with multiple myeloma', Acta Haematologica Polonica, vol. 36, no. 1, pp. 73-79.
Chojnowski, Krzysztof ; Treliński, Jacek ; Kamocka, Malgorzata ; Mielicki, Wojciech P. / Assessment of cancer procoagulant activity in patients with multiple myeloma. In: Acta Haematologica Polonica. 2005 ; Vol. 36, No. 1. pp. 73-79.
@article{5e5bac3b20b1491a803e36bf8217aead,
title = "Assessment of cancer procoagulant activity in patients with multiple myeloma",
abstract = "Pathomechanism of coagulation disorders in multiple myeloma (MM) patients is a complex one but most frequently connected with the presence of monoclonal protein. Until today the role of cancer procoagulant (CP) has not been studied in MM. In the paper CP activity in 26 patients with MM was tested. In 31{\%} of patients elevated levels of CP activity above baseline was observed. Mean CP activity was higher in MM group than in control but without statistical significance. No major differences between mean CP activity in II and III stage of the disease MM type, and no correlation between CP activity and the concentration of monoclonal protein was seen. In none of the patients with CP activity above normal any thrombotic complications were observed.",
keywords = "Cancer procoagulant, Myeloma multiplex, Thrombosis",
author = "Krzysztof Chojnowski and Jacek Treliński and Malgorzata Kamocka and Mielicki, {Wojciech P.}",
year = "2005",
language = "English (US)",
volume = "36",
pages = "73--79",
journal = "Acta Haematologica Polonica",
issn = "0001-5814",
publisher = "Elsevier Urban and Partner sp. z o.o.",
number = "1",

}

TY - JOUR

T1 - Assessment of cancer procoagulant activity in patients with multiple myeloma

AU - Chojnowski, Krzysztof

AU - Treliński, Jacek

AU - Kamocka, Malgorzata

AU - Mielicki, Wojciech P.

PY - 2005

Y1 - 2005

N2 - Pathomechanism of coagulation disorders in multiple myeloma (MM) patients is a complex one but most frequently connected with the presence of monoclonal protein. Until today the role of cancer procoagulant (CP) has not been studied in MM. In the paper CP activity in 26 patients with MM was tested. In 31% of patients elevated levels of CP activity above baseline was observed. Mean CP activity was higher in MM group than in control but without statistical significance. No major differences between mean CP activity in II and III stage of the disease MM type, and no correlation between CP activity and the concentration of monoclonal protein was seen. In none of the patients with CP activity above normal any thrombotic complications were observed.

AB - Pathomechanism of coagulation disorders in multiple myeloma (MM) patients is a complex one but most frequently connected with the presence of monoclonal protein. Until today the role of cancer procoagulant (CP) has not been studied in MM. In the paper CP activity in 26 patients with MM was tested. In 31% of patients elevated levels of CP activity above baseline was observed. Mean CP activity was higher in MM group than in control but without statistical significance. No major differences between mean CP activity in II and III stage of the disease MM type, and no correlation between CP activity and the concentration of monoclonal protein was seen. In none of the patients with CP activity above normal any thrombotic complications were observed.

KW - Cancer procoagulant

KW - Myeloma multiplex

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=18944407709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944407709&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 73

EP - 79

JO - Acta Haematologica Polonica

JF - Acta Haematologica Polonica

SN - 0001-5814

IS - 1

ER -